Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation
: Numerous case reports describe patients with previously documented immunity developing active hepatitis B virus (HBV) infection after transplantation. However, the risk of reactivation of HBV under long‐term immunosuppression in hepatitis B core antibody (HBcAb)‐positive, hepatitis B surface antig...
Gespeichert in:
Veröffentlicht in: | Transplant infectious disease 2003-09, Vol.5 (3), p.126-131 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 131 |
---|---|
container_issue | 3 |
container_start_page | 126 |
container_title | Transplant infectious disease |
container_volume | 5 |
creator | Duhart Jr, B.T. Honaker, M.R. Shokouh-Amiri, M.H. Riely, C.A. Vera, S.R. Taylor, S.L. Al-jedai, A.H. Gaber, A.O. |
description | : Numerous case reports describe patients with previously documented immunity developing active hepatitis B virus (HBV) infection after transplantation. However, the risk of reactivation of HBV under long‐term immunosuppression in hepatitis B core antibody (HBcAb)‐positive, hepatitis B surface antigen (HBsAg)‐negative transplant recipients has not been clearly described. Herein, we present a long‐term follow‐up for 49 HBcAb‐positive, HBsAg‐negative recipients (27 liver, 18 kidney, 4 pancreas) transplanted between June 1996 and April 2001. Among these, 37 recipients (76%) were HBsAb positive at transplantation. Immunosuppression consisted of various antibody induction regimens in 20 (41%) of the recipients with either tacrolimus (33 [67%])‐ or cyclosporine (16 [33%])‐based maintenance immunosuppression. The incidence and duration of HBV prophylaxis was not significant. No patient received hepatitis B immunoglobulin (HBIG) before or after transplantation. Additionally, only two patients received lamivudine, which was started post transplant without clinical indication. The mean length of follow‐up was 3.1±1.4 years. At the last follow‐up, overall patient and graft survival were 98% and 96%, respectively. Patient survival was 96% in liver, 100% in kidney, and 100% in pancreas transplant recipients. The graft survival for each organ type was 93% in liver, 100% in kidney, and 75% in pancreas transplant recipients at the end of follow‐up. There was no incidence of HBV reactivation defined as recurrence of HBsAg and/or HBV DNA positivity. These data suggest that the risk of reactivation of HBV in HBcAb‐positive, HBsAg‐negative transplant recipients under immunosuppression is negligible, regardless of immunosuppressive regimen, lamivudine prophylaxis, or HBsAb status. These patients should have access to transplantation as they enjoy excellent patient and graft survival rates. |
doi_str_mv | 10.1034/j.1399-3062.2003.00021.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71372854</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17121743</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3781-6f2102eb9f6d9b69851f499aa15496262ef52feb961fc8512fd66cbc57c965a73</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhi0Eoh_wF1AucEvwR2zHEhcobam0KhVaxAXJ8nrHqrfZTbCd7fbf42xW7bE9eTTv83pG7yBUEFwRzOrPq4owpUqGBa0oxqzCGFNS7V6h40fh9b5uSkolO0InMa4wJlLV6i06IrUgkmF8jP7-ghS62INNfgsFbE07mOS7TdG5It1CEXy8G-tb6HM_-Vh8K7Y-DLEIYEbTRBuXIBQpmE3sW7NJ--479MaZNsL7w3uKfl-cz89-lLOfl1dnX2elZbIhpXCUYAoL5cRSLYRqOHG1UsYQXitBBQXHqcu6IM5mkbqlEHZhubRKcCPZKfo0_duH7t8AMem1jxbavAh0Q9SSMEkbXj8LEkkokTXLYDOBNocTAzjdB7824UETrMcT6JUek9Zj0no8gd6fQO-y9cNhxrBYw_LJeMg8Ax8PgInWtC5nZn184jglrBY8c18m7t638PDiBfT86nsusr2c7D4m2D3aTbjTQjLJ9Z_rS31zzW_YbM71jP0H_tqxYA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17121743</pqid></control><display><type>article</type><title>Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Duhart Jr, B.T. ; Honaker, M.R. ; Shokouh-Amiri, M.H. ; Riely, C.A. ; Vera, S.R. ; Taylor, S.L. ; Al-jedai, A.H. ; Gaber, A.O.</creator><creatorcontrib>Duhart Jr, B.T. ; Honaker, M.R. ; Shokouh-Amiri, M.H. ; Riely, C.A. ; Vera, S.R. ; Taylor, S.L. ; Al-jedai, A.H. ; Gaber, A.O.</creatorcontrib><description>: Numerous case reports describe patients with previously documented immunity developing active hepatitis B virus (HBV) infection after transplantation. However, the risk of reactivation of HBV under long‐term immunosuppression in hepatitis B core antibody (HBcAb)‐positive, hepatitis B surface antigen (HBsAg)‐negative transplant recipients has not been clearly described. Herein, we present a long‐term follow‐up for 49 HBcAb‐positive, HBsAg‐negative recipients (27 liver, 18 kidney, 4 pancreas) transplanted between June 1996 and April 2001. Among these, 37 recipients (76%) were HBsAb positive at transplantation. Immunosuppression consisted of various antibody induction regimens in 20 (41%) of the recipients with either tacrolimus (33 [67%])‐ or cyclosporine (16 [33%])‐based maintenance immunosuppression. The incidence and duration of HBV prophylaxis was not significant. No patient received hepatitis B immunoglobulin (HBIG) before or after transplantation. Additionally, only two patients received lamivudine, which was started post transplant without clinical indication. The mean length of follow‐up was 3.1±1.4 years. At the last follow‐up, overall patient and graft survival were 98% and 96%, respectively. Patient survival was 96% in liver, 100% in kidney, and 100% in pancreas transplant recipients. The graft survival for each organ type was 93% in liver, 100% in kidney, and 75% in pancreas transplant recipients at the end of follow‐up. There was no incidence of HBV reactivation defined as recurrence of HBsAg and/or HBV DNA positivity. These data suggest that the risk of reactivation of HBV in HBcAb‐positive, HBsAg‐negative transplant recipients under immunosuppression is negligible, regardless of immunosuppressive regimen, lamivudine prophylaxis, or HBsAb status. These patients should have access to transplantation as they enjoy excellent patient and graft survival rates.</description><identifier>ISSN: 1398-2273</identifier><identifier>EISSN: 1399-3062</identifier><identifier>DOI: 10.1034/j.1399-3062.2003.00021.x</identifier><identifier>PMID: 14617300</identifier><language>eng</language><publisher>Oxford, UK: Munksgaard International Publishers</publisher><subject>Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Female ; HBV ; Hepatitis B - virology ; Hepatitis B Antibodies - blood ; Hepatitis B Core Antigens - immunology ; Hepatitis B Surface Antigens - analysis ; Hepatitis B virus ; Hepatitis B virus - physiology ; Human viral diseases ; Humans ; Infectious diseases ; Male ; Medical sciences ; Middle Aged ; Organ Transplantation - adverse effects ; Pharmacology. Drug treatments ; reactivation ; Retrospective Studies ; Risk Factors ; transplantation ; Viral diseases ; Viral hepatitis ; Virus Activation</subject><ispartof>Transplant infectious disease, 2003-09, Vol.5 (3), p.126-131</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3781-6f2102eb9f6d9b69851f499aa15496262ef52feb961fc8512fd66cbc57c965a73</citedby><cites>FETCH-LOGICAL-c3781-6f2102eb9f6d9b69851f499aa15496262ef52feb961fc8512fd66cbc57c965a73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1034%2Fj.1399-3062.2003.00021.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1034%2Fj.1399-3062.2003.00021.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15213465$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14617300$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Duhart Jr, B.T.</creatorcontrib><creatorcontrib>Honaker, M.R.</creatorcontrib><creatorcontrib>Shokouh-Amiri, M.H.</creatorcontrib><creatorcontrib>Riely, C.A.</creatorcontrib><creatorcontrib>Vera, S.R.</creatorcontrib><creatorcontrib>Taylor, S.L.</creatorcontrib><creatorcontrib>Al-jedai, A.H.</creatorcontrib><creatorcontrib>Gaber, A.O.</creatorcontrib><title>Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation</title><title>Transplant infectious disease</title><addtitle>Transpl Infect Dis</addtitle><description>: Numerous case reports describe patients with previously documented immunity developing active hepatitis B virus (HBV) infection after transplantation. However, the risk of reactivation of HBV under long‐term immunosuppression in hepatitis B core antibody (HBcAb)‐positive, hepatitis B surface antigen (HBsAg)‐negative transplant recipients has not been clearly described. Herein, we present a long‐term follow‐up for 49 HBcAb‐positive, HBsAg‐negative recipients (27 liver, 18 kidney, 4 pancreas) transplanted between June 1996 and April 2001. Among these, 37 recipients (76%) were HBsAb positive at transplantation. Immunosuppression consisted of various antibody induction regimens in 20 (41%) of the recipients with either tacrolimus (33 [67%])‐ or cyclosporine (16 [33%])‐based maintenance immunosuppression. The incidence and duration of HBV prophylaxis was not significant. No patient received hepatitis B immunoglobulin (HBIG) before or after transplantation. Additionally, only two patients received lamivudine, which was started post transplant without clinical indication. The mean length of follow‐up was 3.1±1.4 years. At the last follow‐up, overall patient and graft survival were 98% and 96%, respectively. Patient survival was 96% in liver, 100% in kidney, and 100% in pancreas transplant recipients. The graft survival for each organ type was 93% in liver, 100% in kidney, and 75% in pancreas transplant recipients at the end of follow‐up. There was no incidence of HBV reactivation defined as recurrence of HBsAg and/or HBV DNA positivity. These data suggest that the risk of reactivation of HBV in HBcAb‐positive, HBsAg‐negative transplant recipients under immunosuppression is negligible, regardless of immunosuppressive regimen, lamivudine prophylaxis, or HBsAb status. These patients should have access to transplantation as they enjoy excellent patient and graft survival rates.</description><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>HBV</subject><subject>Hepatitis B - virology</subject><subject>Hepatitis B Antibodies - blood</subject><subject>Hepatitis B Core Antigens - immunology</subject><subject>Hepatitis B Surface Antigens - analysis</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - physiology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Organ Transplantation - adverse effects</subject><subject>Pharmacology. Drug treatments</subject><subject>reactivation</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>transplantation</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Virus Activation</subject><issn>1398-2273</issn><issn>1399-3062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1v1DAQhi0Eoh_wF1AucEvwR2zHEhcobam0KhVaxAXJ8nrHqrfZTbCd7fbf42xW7bE9eTTv83pG7yBUEFwRzOrPq4owpUqGBa0oxqzCGFNS7V6h40fh9b5uSkolO0InMa4wJlLV6i06IrUgkmF8jP7-ghS62INNfgsFbE07mOS7TdG5It1CEXy8G-tb6HM_-Vh8K7Y-DLEIYEbTRBuXIBQpmE3sW7NJ--479MaZNsL7w3uKfl-cz89-lLOfl1dnX2elZbIhpXCUYAoL5cRSLYRqOHG1UsYQXitBBQXHqcu6IM5mkbqlEHZhubRKcCPZKfo0_duH7t8AMem1jxbavAh0Q9SSMEkbXj8LEkkokTXLYDOBNocTAzjdB7824UETrMcT6JUek9Zj0no8gd6fQO-y9cNhxrBYw_LJeMg8Ax8PgInWtC5nZn184jglrBY8c18m7t638PDiBfT86nsusr2c7D4m2D3aTbjTQjLJ9Z_rS31zzW_YbM71jP0H_tqxYA</recordid><startdate>200309</startdate><enddate>200309</enddate><creator>Duhart Jr, B.T.</creator><creator>Honaker, M.R.</creator><creator>Shokouh-Amiri, M.H.</creator><creator>Riely, C.A.</creator><creator>Vera, S.R.</creator><creator>Taylor, S.L.</creator><creator>Al-jedai, A.H.</creator><creator>Gaber, A.O.</creator><general>Munksgaard International Publishers</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200309</creationdate><title>Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation</title><author>Duhart Jr, B.T. ; Honaker, M.R. ; Shokouh-Amiri, M.H. ; Riely, C.A. ; Vera, S.R. ; Taylor, S.L. ; Al-jedai, A.H. ; Gaber, A.O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3781-6f2102eb9f6d9b69851f499aa15496262ef52feb961fc8512fd66cbc57c965a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>HBV</topic><topic>Hepatitis B - virology</topic><topic>Hepatitis B Antibodies - blood</topic><topic>Hepatitis B Core Antigens - immunology</topic><topic>Hepatitis B Surface Antigens - analysis</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - physiology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Organ Transplantation - adverse effects</topic><topic>Pharmacology. Drug treatments</topic><topic>reactivation</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>transplantation</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Virus Activation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Duhart Jr, B.T.</creatorcontrib><creatorcontrib>Honaker, M.R.</creatorcontrib><creatorcontrib>Shokouh-Amiri, M.H.</creatorcontrib><creatorcontrib>Riely, C.A.</creatorcontrib><creatorcontrib>Vera, S.R.</creatorcontrib><creatorcontrib>Taylor, S.L.</creatorcontrib><creatorcontrib>Al-jedai, A.H.</creatorcontrib><creatorcontrib>Gaber, A.O.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transplant infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Duhart Jr, B.T.</au><au>Honaker, M.R.</au><au>Shokouh-Amiri, M.H.</au><au>Riely, C.A.</au><au>Vera, S.R.</au><au>Taylor, S.L.</au><au>Al-jedai, A.H.</au><au>Gaber, A.O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation</atitle><jtitle>Transplant infectious disease</jtitle><addtitle>Transpl Infect Dis</addtitle><date>2003-09</date><risdate>2003</risdate><volume>5</volume><issue>3</issue><spage>126</spage><epage>131</epage><pages>126-131</pages><issn>1398-2273</issn><eissn>1399-3062</eissn><abstract>: Numerous case reports describe patients with previously documented immunity developing active hepatitis B virus (HBV) infection after transplantation. However, the risk of reactivation of HBV under long‐term immunosuppression in hepatitis B core antibody (HBcAb)‐positive, hepatitis B surface antigen (HBsAg)‐negative transplant recipients has not been clearly described. Herein, we present a long‐term follow‐up for 49 HBcAb‐positive, HBsAg‐negative recipients (27 liver, 18 kidney, 4 pancreas) transplanted between June 1996 and April 2001. Among these, 37 recipients (76%) were HBsAb positive at transplantation. Immunosuppression consisted of various antibody induction regimens in 20 (41%) of the recipients with either tacrolimus (33 [67%])‐ or cyclosporine (16 [33%])‐based maintenance immunosuppression. The incidence and duration of HBV prophylaxis was not significant. No patient received hepatitis B immunoglobulin (HBIG) before or after transplantation. Additionally, only two patients received lamivudine, which was started post transplant without clinical indication. The mean length of follow‐up was 3.1±1.4 years. At the last follow‐up, overall patient and graft survival were 98% and 96%, respectively. Patient survival was 96% in liver, 100% in kidney, and 100% in pancreas transplant recipients. The graft survival for each organ type was 93% in liver, 100% in kidney, and 75% in pancreas transplant recipients at the end of follow‐up. There was no incidence of HBV reactivation defined as recurrence of HBsAg and/or HBV DNA positivity. These data suggest that the risk of reactivation of HBV in HBcAb‐positive, HBsAg‐negative transplant recipients under immunosuppression is negligible, regardless of immunosuppressive regimen, lamivudine prophylaxis, or HBsAb status. These patients should have access to transplantation as they enjoy excellent patient and graft survival rates.</abstract><cop>Oxford, UK</cop><pub>Munksgaard International Publishers</pub><pmid>14617300</pmid><doi>10.1034/j.1399-3062.2003.00021.x</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1398-2273 |
ispartof | Transplant infectious disease, 2003-09, Vol.5 (3), p.126-131 |
issn | 1398-2273 1399-3062 |
language | eng |
recordid | cdi_proquest_miscellaneous_71372854 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Female HBV Hepatitis B - virology Hepatitis B Antibodies - blood Hepatitis B Core Antigens - immunology Hepatitis B Surface Antigens - analysis Hepatitis B virus Hepatitis B virus - physiology Human viral diseases Humans Infectious diseases Male Medical sciences Middle Aged Organ Transplantation - adverse effects Pharmacology. Drug treatments reactivation Retrospective Studies Risk Factors transplantation Viral diseases Viral hepatitis Virus Activation |
title | Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A15%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retrospective%20evaluation%20of%20the%20risk%20of%20hepatitis%20B%20virus%20reactivation%20after%20transplantation&rft.jtitle=Transplant%20infectious%20disease&rft.au=Duhart%20Jr,%20B.T.&rft.date=2003-09&rft.volume=5&rft.issue=3&rft.spage=126&rft.epage=131&rft.pages=126-131&rft.issn=1398-2273&rft.eissn=1399-3062&rft_id=info:doi/10.1034/j.1399-3062.2003.00021.x&rft_dat=%3Cproquest_cross%3E17121743%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17121743&rft_id=info:pmid/14617300&rfr_iscdi=true |